Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.

News | Clinical Decision Support

Computerized Decision Support System Helps to Reduce Cardiovascular Risk Factors in Patients with Diabetes

December 7, 2022 — Compared with team-based care alone, the addition of a computerized clinical decision support system ...

December 07, 2022

Nicholas Pajewski, Ph.D., associate professor of biostatistics and data science at Wake Forest University School of Medicine. Credit: Wake Forest University School of Medicine

News | Hypertension

Study Highlights Importance of Long-term Management of Hypertension

November 23, 2022 — In 2015, published findings from the landmark Systolic Blood Pressure Intervention Trial (SPRINT) sh ...

November 23, 2022

Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo)

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

November 09, 2022

CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

News | Hypertension

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

October 24, 2022 — CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly ...

October 24, 2022

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from ...

October 05, 2022

Study of the Paradise Ultrasound Renal Denervation System Shows Significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension

News | Hypertension

ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting

September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...

September 26, 2022

Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II study

News | Hypertension

Orchestra BioMed Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT at TCT 2022

September 20, 2022 — Orchestra BioMed, Inc., a biomedical innovation company accelerating high-impact technologies to ...

September 20, 2022

Computed tomography 3D surface rendering of the lungs and heart from a patient with pulmonary arterial hypertension demonstrating trachea and major airways (yellow), an enlarged heart (red), enlarged main pulmonary artery (large blue vessel on top of heart) and thinning of the peripheral pulmonary vessels (blue). Marcus Y. Chen, M.D., NHLBI

News | Hypertension

Novel Blood Test Helps Evaluate Severity in Pulmonary Arterial Hypertension, a Rare Lung Disease

September 12, 2022 — Researchers at the National Institutes of Health have found that a novel blood test can be used to ...

September 12, 2022

The illustration shows a portion of the receptor pGC-A, known as the extracellular domain, which protrudes from cell surfaces in the cardiovascular system. Small molecules bind with the receptor and exert subtle control over blood pressure. The new research offers the first sneak peek at the full-length receptor, a vital step in the development of new drugs to treat hypertension and other afflictions.

News | Hypertension

New Study Explores Cell Receptor Crucial for Cardiovascular Health

August 8, 2022 — Cardiovascular diseases remain a leading cause of death around the world. A primary contributor to ...

August 08, 2022

RADIANCE II US FDA IDE pivotal trial evaluating the Paradise Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension met its primary efficacy endpoint, demonstrating a statistically significant reduction in daytime ambulatory systolic blood pressure between treatment and a sham procedure measured at two months

News | Hypertension

ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise System for the Treatment of Hypertension

July 29, 2022 — ReCor Medical, Inc. and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings ...

July 29, 2022

Back on track after its in-person hiatus, ACC22 stressed industry resilience, and featured practice-changing science and innovations

Feature | ACC | By Melinda Taschetta-Millane

ACC22: Transforming Cardiovascular Care

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

May 11, 2022

Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine, Nnitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level.

News | Heart Failure

Pfizer Issues Voluntary Nationwide Recall of ACCUPRIL (Quinapril HCl)

April 25, 2022 — Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer ...

April 25, 2022